GlassScriptPhysician profile
Rajesh Shetty
NPI 1538159454
$49,454.50
in general payments reported to CMS, 2019-2025
38 companies · $2,821 in 2025
The $2,821 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,299 · 2020: $7,965 · 2021: $7,706 · 2022: $6,925 · 2023: $11K · 2024: $4,066 · 2025: $2,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,791 · Consulting Fee: $6,270 · Travel and Lodging: $1,448 · Honoraria: $51.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,790.56 |
| Consulting Fee | $6,270.00 |
| Travel and Lodging | $1,447.88 |
| Honoraria | $51.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $19,242.70 | 2019-2021 | |
| Alcon Vision LLC | $16,864.14 | 2019-2025 | Argos, Clareon, Lensx |
| Sight Sciences, INC. | $2,303.20 | 2019-2025 | Omni Surgical System |
| Abbvie INC. | $1,554.28 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Glaukos Corporation | $1,334.23 | 2019-2025 | Idosetr, Idose Tr, Istent |
| New World Medical,INC. | $1,152.91 | 2019-2025 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Rxsight INC | $1,129.75 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $770.66 | 2019-2022 | |
| Biotissue Holdings INC. | $714.72 | 2019-2025 | |
| Harrow Eye, LLC | $425.91 | 2024-2025 | Iheezo, Triesence |
| Bausch & Lomb Americas INC. | $424.13 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $403.57 | 2019-2021 | |
| Lensar, INC. | $361.17 | 2020-2024 | Lensar Laser System |
| Carl Zeiss Meditec USA, INC. | $337.90 | 2022-2025 | Iolmaster 700 |
| Johnson & Johnson Surgical Vision, INC. | $333.68 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $258.00 | 2023 | |
| Horizon Therapeutics Plc | $256.85 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $256.74 | 2019-2025 | |
| Oyster Point Pharma, INC. | $210.88 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $190.91 | 2019 | |
| Iridex Corporation | $151.57 | 2021-2022 | |
| Dutch Ophthalmic, USA | $132.75 | 2025 | Tissueblue, Eva, Combined Machine |
| Dompe US, INC. | $125.00 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $109.18 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $92.62 | 2024-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Ani Pharmaceuticals, INC. | $48.74 | 2025 | Purified Cortrophin Gel |
| Topcon Healthcare, INC. | $42.99 | 2023-2024 | |
| Heru, INC. | $37.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.11 | 2019 | |
| Ivantis, INC | $28.51 | 2020 | |
| Medtronic Vascular, INC. | $26.87 | 2019 | |
| Apellis Pharmaceuticals, INC. | $23.29 | 2025 | Syfovre |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyepoint US, INC. | $18.52 | 2021 | |
| Omeros Corporation | $18.38 | 2020 | |
| Novo Nordisk INC | $15.96 | 2022 | |
| Topcon Healthcare Solutions, INC. | $7.33 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.